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Next-generation	sequencing	has	critical	applications	 in	vi-
rus	discovery,	diagnostics,	and	environmental	surveillance.	
We	used	metagenomic	sequence	libraries	for	retrospective	
screening	 of	 plasma	 samples	 for	 the	 recently	 discovered	
human	hepegivirus	1	(HHpgV-1).	From	a	cohort	of	150	hep-
atitis	C	virus	(HCV)–positive	case-patients,	we	identified	2	
persons	with	HHpgV-1	viremia	and	a	high	frequency	of	hu-
man	pegivirus	(HPgV)	viremia	(14%).	Detection	of	HHpgV-1	
and	HPgV	was	concordant	with	parallel	PCR-based	screen-
ing	 using	 conserved	 primers	 matching	 groups	 1	 (HPgV)	
and	2	 (HHPgV-1)	nonstructural	3	 region	sequences.	PCR	
identified	1	HHPgV-1–positive	person	with	viremia	 from	a	
group	of	 195	persons	with	 hemophilia	who	had	been	ex-
posed	to	nonvirally	 inactivated	factor	VII/IX;	18	(9%)	were	
HPgV-positive.	Relative	to	HCV	and	HPgV,	active	infections	
with	HHpgV-1	were	infrequently	detected	in	blood,	even	in	
groups	that	had	substantial	parenteral	exposure.	Our	find-
ings	are	consistent	with	lower	transmissibility	or	higher	rates	
of	 virus	clearance	 for	HHpgV-1	 than	 for	other	bloodborne	
human	flaviviruses.
The development of next-generation sequencing meth-ods and related molecular tools has greatly increased 
the pace of virus discovery (1,2), and these methods have 
become widely used for the investigation of novel zoonotic 
infections. Examples in which next-generation sequencing 
methods have identified novel viral agents associated with 
disease outbreaks include severe fever with thrombocyto-
penia virus (SFTV) in China (3), a bunyavirus in the United 
States (4), and a novel rhabdovirus in Central Africa (5). 
Using such methods, 2 authors of this study (A.K. and P.S.) 
recently described a novel flavivirus, distantly related to 
human pegivirus (HPgV, formerly described as GB virus 
C or hepatitis G virus) but with several genome attributes, 
such as a type IV internal ribosomal entry site (IRES), pos-
session of a core-like protein, and a heavily glycosylated 
envelope protein that show greater affinity with hepatitis C 
virus (HCV) and other members of the genus Hepacivirus 
(6). The virus, named human hepegivirus 1 (HHpgV-1) to 
reflect these mosaic characteristics, was detected in 2 blood 
recipients and as a persistent infection in 2 persons with 
hemophilia exposed previously to nonvirally inactivated 
factor VIII/IX concentrates.
Following the example of the previous use of metage-
nomic libraries to detect human pathogens (7–9), we devel-
oped a bioinformatics-based method to screen existing li-
braries for HHpgV-1 and HPgV sequences from previously 
tested persons in the United Kingdom, enabling viremia 
frequencies in different risk groups to be estimated. Sam-
ples used to generate libraries with and without HHpgV-1 
sequences were retrieved and used to validate the specific-
ity and sensitivity of a newly developed reverse transcrip-
tion PCR (RT-PCR)–based method for sample screening. 
This method was subsequently used to screen samples from 
patients extensively treated with nonvirally inactivated fac-
tor VIII or IX concentrates and controls.
Methods
Samples
We obtained samples from 195 persons with hemophilia 
from the Hemophilia Growth and Development Study 
(HGDS) cohort (10). We obtained metagenomic datas-
ets used for bioinformatic screening from OxBRC Pro-
spective Cohort Study in Hepatitis C (ethics reference 
09/H0604/20), the Short Pulse Antiretroviral Therapy at 
seroConversion cohort (11), Thames Valley HIV Cohort 
Study (12), and a cohort in the Democratic Republic of 
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the Congo (DRC) (13). All datasets were derived by using 
nontargeted viral RNaseq from total plasma RNA and the 
Illumina Hiseq sequencing platform (Illumina Inc., San 
Diego, CA, USA).
Screening Assays for Group 1 and  
Group 2 Pegiviruses
RNA was extracted from 200 mL of pooled or 20 mL of 
individual plasma by using the RNeasy Kit (QIAGEN, 
Hilden, Germany) and recovered in 30 mL of nuclease-
free water. First-strand cDNA was synthesized from 6 mL 
of recovered RNA by using Superscript III reverse tran-
scription (Life Technologies, Carlsbad, CA, USA) with 
random hexamer primers. Nested PCRs were performed 
by using GoTaq DNA polymerase (Promega, Madison, 
WI, USA) and the primers described in Table 1. First 
round reactions were obtained by using 2 mL of cDNA as 
a template under these conditions: 40 cycles of 18 seconds 
at 94°C, 21 seconds at 50°C and 60 seconds at 72°C, and 
a final extension step of 5 minutes at 72°C. Second round 
reactions were done by using 2 mL of first round template 
under identical conditions.
Metagenomic Sequencing and Bioinformatics
Metagenomic datasets used in this study had previously 
been sequenced on the Illumina platform from sequenc-
ing libraries synthesized with either the NEBNext mRNA 
Sample Prep Kit for Illumina (New England Biolabs, Ips-
wich, MA, USA), or the NEBNext Ultra Directional RNA 
Library Prep Kit for Illumina (New England Biolabs) with 
modifications to the manufacturer’s protocols (10). Datas-
ets in .bam format were depleted of human reads by using 
the bowtie method to map them to the HG19 human genome 
and convert them to fasta files by using custom awk scripts, 
then were piped to the blastn program (BLAST+ version 
2.2.25; http://blast.ncbi.nlm.nih. gov/Blast.cgi) by using 
a nucleotide database of all GenBank viral reference ge-
nomes and the initial HHpgV-1 variant, AK-790 (GenBank 
accession no. KT439329). All hits with E values <0.01 
were accepted. Datasets containing HHPgV-1 or HPgV-1 
sequence data were subjected to a custom-made assembly 
pipeline by which reads were trimmed of low PHRED qual-
ity bases (QUASR, Sourceforge, http://wwwsourceforge.
net) and adaptor sequences, before virus reads (identified 
by using blastn) were assembled by using Vicuna (14) and 
VFAT software (http://www.broadinstitute.org/scientific-
community/science/projects/viral-genomics/v-fat). 
RNA folding energies and ratios of non-synonymous 
to synonymous nucleotide substitutions (dN/dS) were cal-
culated for consensus whole-genome sequences by using 
SSE version 1.2 (15). Complete genome sequences of HH-
pgV-1 and HPgV obtained in this study have been submit-
ted to GenBank (accession nos. LT009476–LT009494).
Results
Library Screening in Silico
We used the assembled sequence of AK-790 as a reference 
to screen libraries of metagenomic sequence reads derived 
from plasma samples from 120 HCV-infected persons (pri-
marily infected through injected drugs), 36 persons infected 
with HIV-1 from sexual contact, and 30 persons who were 
co-infected with HCV and HIV-1 (Table 2). From these 
samples, a total of 3 sequence libraries contained HHpgV-1 
sequences. However, only 2 reads were detected in sample 
D1212, and these were identical in sequence to those of 
D1220. Because of the possibility of extraneous contami-
nation of either the sample position in the sequencer or of 
the sequence dataset (e.g., through misidentified tags), we 
provisionally considered D1212 to be HHpgV-1 negative.
By using the sequence reads, we obtained near-com-
plete genome sequences of HHpgV-1 from the 2 positive 
samples (Table 2); their divergence, and other sequence 
characteristics were compared with those of the AK-790 pro-
totype sequence (Figure 1; Table 3). Sequences were >99% 
complete with 5′ and 3′ ends approximately co-terminus 
with the HHpgV-1 prototype sequence (D1255 and D1220 
lacked 12 and 23 bases at the 5′ end, respectively, and 
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Table 1. Primer	sequences	used	for	PCR	screening	of	HPgV groups 
Orientation Position† Sequence,	5′ 3′ 
HHpgV-1/group	2	primers   
 Sense,	outer 4,488 CGTSGTSMTYTGYGACGAGTGCCA 
 Antisense,	outer 5,021 CCRCGCCGCTGCATVCGSAAYGC 
 Sense,	inner 4,723 CAYGYDATCTTYTGYCACTCGAAGG 
 Antisense,	inner 4,900 CRAAGTTBCCDGTGTAGCCDGTGGA 
HPgV/group	1	primers   
 Orientation Position‡  
 Sense,	outer 3,931 GSGCNATGGGNCCNTAYATGGA 
 Antisense,	outer 4,546 GTNACYTCVACNACCTCCTCYACCA 
 Sense,	inner 4,092 GTGGTNATHTGYGAYGAGTGYCA 
 Antisense,	inner 4,357 TCRCACTCMRCCTTKGARTGRCARAA 
*HHpgV,	human	hepegivirus;	HPgV,	human	pegivirus.	 
†Position of 5′ base	in	the	AK-790	genome	(GenBank	accession	no.	KT439329). 
‡Position	of	5′ base	in	the	HPgV	Iowa	genome	(GenBank	accession	no.	AF121950). 
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D1255 had a 23 base extension at the 3′ end). Sequences 
were ≈5% divergent from each other and from AK-790 
over the length of the genome; most were at synonymous 
sites that left protein encoding unchanged (dN/dS 0.170–
0.193). Sequences were also phylogenetically distinct from 
the larger dataset of variants sequenced in the nonstructural 
3 (NS3) region (Figure 2; 6,16). Genomes of both HHp-
gV-1 variants showed bioinformatic evidence for genome 
scale–ordered RNA structure (17), with mean folding en-
ergy differences in the coding region of 7.6% and 8.3% for 
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Table 2. Detection frequencies of HPgV by	sequence	library	screening	and	PCR* 
Diagnostic	method Diagnoses	and	characteristics No.	tested No.	(%)	HHpgV-1+	 No.	(%)	HPgV+ 
Bioinformatics     
 HIV+ 36 0 3	(8.3) 
 HIV+/HCV+/PWID 30 0 3	(10.0) 
 HCV+/PWID 120 2	(1.7) 14	(11.6) 
PCR     
 Hemophilia† 195 1	(0.5) 18	(9.2) 
 Control	group‡ 50 0 1	(2.0) 
*HPgV,	human	pegivirus;	HHpgV,	human	hepegivirus; +,	positive;HCV,	hepatitis	C	virus;	PWID,	persons	who	inject	drugs. 
†Previously exposed to virally inactivated factor VIII/IX; all seropositive for HCV. 
‡No	history	of	parenteral	exposure;	HIV-1	and	HCV	negative. 
 
Figure 1. Maximum-likelihood	
phylogenetic	analysis	of	complete	
genome	sequences	of	human	
pegivirus	assembled	in	this	study	
(black	circles)	compared	with	
available	human	hepegivirus	(HPgV)	
sequences	of	genotypes	1–6	
published	in	GenBank	(accession	
numbers	shown).	The	tree	was	
constructed	by	using	the	maximum-
likelihood	algorithm	implemented	
in	the	MEGA6	software	package	
(16).	For	this	dataset,	the	optimum	
maximum	model	was	general	time	
reversible	model	(18)	with	a	gamma	
distribution	(5	rates)	and	invariant	
sites.	Phylogenetic	analysis	of	
each	dataset	used	100	bootstrap	
resamplings	to	infer	the	robustness	
of	groupings.	Genotypes	previously	
assigned	to	HPgV	sequences	are	
shown	on	the	right	with	the	exception	
of	sequence	AB013501	(from	
the	United	Kingdom,	shown	with	
genotype	“?”).	Scale	bar	indicates	
nucleotide	substitutions	per	site.
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samples D1255 and D1220, respectively, which is similar 
to that calculated for AK-790 (7.6%) but lower than that 
calculated for HPgV (Table 3) and other pegiviruses (6).
The 2 HHPgV-1 samples originated from HCV-infect-
ed men enrolled in the OxBRC Prospective Cohort Study in 
Hepatitis C; samples were collected before initiation of an-
tiviral treatment with telaprevir, pegylated-interferon, and 
ribavirin. Sample D1255 was collected from a person with 
a history of injection drug use, 50 years of age, 12 weeks 
before successful eradication of HCV genotype 1b virus; at 
the time of the study, he had remained under observation 
for a segment IV liver lesion, cirrhosis, and raised alphafe-
toprotein. Sample D1220 was collected from a patient 58 
years of age who had genotype 1a HCV infection and died 
from decompensated liver failure 4 weeks into treatment. 
Both patients denied receiving blood or donor blood–de-
rived products at the time of enrollment, and neither patient 
received blood products before sampling, according to hos-
pital medical records and local transfusion service records.
As a control for the bioinformatic screening method, 
the same samples were screened for human pegivirus 
(HPgV) by using 60 whole pegivirus genomes from the US 
National Center for Biotechnology Information nucleotide 
database (http://www.ncbi.nlm.nih.gov/nuccore) as refer-
ences for blastn filtering (Table 2). A total of 20 sample 
libraries contained at least 10 HPgV-matching reads and 
showed a median of 8,185 reads (IQR 5207–15,863), 
equating 17,000 to 19 million total sequenced bases (Table 
3). Near-complete genome sequences could be assembled 
from 17 of the libraries, and reduced genome coverage 
obtained from the 3 samples with sequence read totals 
<100,000. The sequence characteristics of the HPgV se-
quences were typical for members of this virus group: mod-
erate sequence divergence between each other and to the 
HPgV reference sequence (9%–13%), extremely low dN/
dS ratios (0.022–0.049) and evidence for extensive internal 
RNA secondary structure (mean folding energy differences 
of 10.5%–13.2%; Table 3). Persons infected with HPgV 
originating from the UK were infected with genotype 2, 
and those from South Africa harbored genotypes 1 and 
5 (Figure 1; 18). The exception was patient 89860282, a 
UK resident man enrolled in the Short Pulse Antiretro-
viral Therapy at seroConversion trial who was infected 
with a candidate novel genotype pegivirus in addition to a 
clade B HIV-1.
In addition to being detected at a lower frequency 
than HPgV in groups that listed sexual contact and inject-
ed drug use as potential risk factors for infection (Table 
2), read totals for HHpgV-1 were >2 SDs below mean 
totals for HPgV. This finding is consistent with a lower 
degree of viremia.
Validation of PCR for HHpgV-1
We compared sequences of the 2 HHpgV-1 samples with 
AK-790 and other group 2 pegiviruses (6) to identify 
conserved regions that might serve as binding sites for 
primers suitable for HHpgV-1 screening. A PCR based 
on primers hybridizing to a conserved region of group 2 
pegiviruses (Table 1; 6) and those previously described 
(AK1/AK2) were validated by using the original samples 
identified as positive on bioinformatic screening, the sus-
pected false-positive sample (D1212), and a selection of 
samples in which HHpgV-1 sequences were not detected 
(Table 4). To cross-validate the assay for HPgV detection, 
primers were designed based on regions conserved in the 
NS3 region of group 1 pegiviruses (human, primate, and 
bat pegiviruses; Table 1).
For groups 1 and 2 primers, PCR detection showed 
high concordance with bioinformatic screening (Table 4). 
By using group 2 primers, both samples that contained high 
numbers of HHpgV-1 reads on bioinformatic screening 
tested positive and the suspected negative sample (D1212) 
with only 3 reads was negative, as were the 20 controls 
in libraries that contained no HHpgV-1 sequences. Similar 
concordance between HPgV detection by PCR with library 
screening was observed in parallel (both methods identified 
10 positive samples and 13 negative). The observed con-
cordance between PCR- and bioinformatic-based screening 
methods for both virus groups validates both approaches 
for the wider screening for both virus groups in epidemio-
logic analyses.
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Figure 2. Maximum-likelihood	(ML)	phylogenetic	analysis	of	
human	pegivirus	sequences.	NS3	region	sequences	(positions	
4609–4880	as	numbered	in	the	AK-790	reference	sequence,	
denoted	here	as	tt790)	were	selected	to	overlap	with	sequences	
from	PCR-derived	amplicons	generated	in	this	study	(black	
circles)	and	partial	NS3	region	sequences	reported	previously	
(6).	The	tree	was	constructed	by	using	the	maximum	likelihood	
algorithm	implemented	in	the	MEGA6	software	package	(16).	
The	optimum	ML	model	(lowest	Bayesian	information	criterion	
score	and	typically	greatest	ML	value)	was	Kimura	2	parameter	
and	invariant	sites.	Phylogenetic	analysis	of	each	dataset	used	
100	bootstrap	re-samplings	to	infer	the	robustness	of	groupings.	
The	tree	was	rooted	with	a	rat	pegivirus	sequence	(GenBank	
accession	no.	KC815311,	not	shown).	IDU,	injection	drug	use;	
NS,	nonstructural.	Scale	bar	indicates	nucleotide	substitutions	
per	site.
	Novel	Human	Pegivirus	Evaluation
HHpgV-1 Detection in Case-Patients  
Transfused Multiple Times
We used pegivirus groups 1 and 2 PCRs to screen plasma 
samples from persons with hemophilia exposed to non–vi-
rally inactivated factor VII/IX concentrates and non–paren-
terally exposed controls (Table 2). Persons with hemophil-
ia showed increased frequencies of HPgV viremia when 
compared with controls (18 of 195 compared with 1 of 
50, respectively; Table 2), although this difference did not 
achieve statistical significance (p≈0.069 by Fisher exact 
test). One sample from a person with hemophilia was posi-
tive for HHpgV-1 by using group 2 primers; the amplicon 
sequence was 2.4%–4.8% divergent from AK-790, D1255, 
and D1220 between positions 4498–4896 in the AK-790 
genome, with substitutions predominantly at synonymous 
sites. The sequence was phylogenetically distinct from the 
larger dataset of HHpgV-1 sequenced in the NS3 region 
(Figure 2; 17).
Discussion
This study used a combined approach of bioinformatic 
screening of metagenomic sequence libraries and pegivi-
rus group-specific PCRs to investigate the frequency and 
risk group associations of HHpgV-1 infections. The cross-
validation of these 2 screening methods provides reassur-
ance that the methods used for detection of the 2 pegivirus 
groups were both sensitive and specific, notwithstanding 
the relatively infrequent detection of HHpgV-1 in the 
study populations.
The 2 different screening approaches clearly have 
their own advantages and disadvantages. Bioinformatic 
screening methods are able to detect a much broader range 
of genetic variants of a target virus that would require 
separate PCRs for their detection. As an example, HH-
pgV-1 was originally detected by bioinformatic screening 
of metagenomic libraries by using HPgV as the reference 
sequence (6), but the design of primers capable of detect-
ing all pegiviruses is problematic and in practice may re-
quire separate assays for group 1 and 2 variants as used in 
this study. Metagenomic virtual screening could be eas-
ily extended by the use of multiple reference sequences 
representing a much wider range of viruses than would 
be practical for PCR, for which multiple assays would 
have to be developed, validated, and applied in complex, 
multiplexed formats. Library screening for human patho-
gens has been proposed as alternative to multiplex PCR 
for this purpose (7–9). Another advantage of bioinfor-
matic screening is that it is usually possible to assemble 
near-complete genome sequences of the viruses being 
screened, which provides invaluable information for stud-
ies of its molecular epidemiology, transmission, and evo-
lution. Both HHPgV-1 and 17 of the 20 HPgV variants 
detected by bioinformatic screening could be assembled 
in near-complete genome sequences (Table 3). The HPgV 
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Table 3. Read	depth	and	divergence	of	HPgV sequences	obtained	by	using	metagenomic	screening* 
Virus,	ID	no. Case-patient	origin Type† Length Coverage,	%	 Reads Div, %‡ dN/dS MFED,	%§ 
HHpgV-1, n	=	2         
 D1220 UK NA 9,550 99.8 247,798 4.7 0.193 7.6 
 D1255 UK NA 9,503 99.6 101,951 5.1 0.170 8.3 
HPgV,	n	=	20         
 89859249 UK 2 9,383 99.9 19,231,581 10.0 0.031 11.4 
 89859262 UK 2 9,388 99.8 6,766,497 9.9 0.029 12.4 
 56330218 South	Africa 5 9,364 99.7 4,242,732 13.6 0.043 11.6 
 56330227 Australia 2 9,366 99.7 2,411,508 9.9 0.031 12.0 
 56330281 DRC 1 9,362 99.7 2,297,064 13.5 0.048 13.2 
 67845223 UK 2 9,382 99.9 1,332,130 9.4 0.023 11.5 
 56330260 UK 5 9,365 99.7 1,306,864 13.7 0.043 12.1 
 56330265 UK 2 9,425 99.7 1,178,508 9.5 0.035 12.5 
 56330292 NA 2 9,356 99.6 1,021,219 11.5 0.035 11.9 
 89860237 UK 2 9,367 99.7 953,683 9.5 0.035 11.0 
 56330272 DRC 1 9,340 99.4 707,495 13.6 0.052 12.0 
 56330229 UK 2 9,366 99.7 698,622 11.5 0.036 12.6 
 56330276 DRC 5 9,337 99.4 612,424 13.3 0.042 12.3 
 89860282 UK Novel 8,443 89.9 574,652 13.2 0.049 10.5 
 89860286 UK 2 8,923 95.0 513,420 9.6 0.035 10.3 
 89860260 UK 2 8,983 95.6 512,515 11.6 0.041 10.5 
 56330286 NA 2 9,355 99.6 454,106 9.6 0.022 12.5 
 56330228 Australia ND 436 4.6 68,351 8.6 0.019 ND 
 56330250 UK ND 423 4.5 38,083 11.6 0.043 ND 
 89860212 UK ND 1,117 11.9 17,226 8.6 0.068 ND 
*HPgV,	human	pegivirus;	ID,	identification;	Div,	sequence	divergence;	dN/dS:	ratio	of	nonsynonymous	(dN)	to	synonymous	(dS)	substitutions;	MFED, 
mean	folding	energy	difference;	HHpgV,	human	hepegivirus;	UK, United Kingdom;	NA,	not	applicable	(no	genotypes	of	HHpgV-1	are	currently	assigned);	
DRC,	Democratic	Republic	of	Congo;	ND,	not	done	(insufficient	sequence	length). 
†Genotype based on phylogenetic analysis of complete genome sequences (Figure 1).  
‡Comparison with AK790 prototype sequence (HHPgV-1)	or	AF121950	(HPgV;	genotype	2). 
§Difference	in	minimum	folding	energy	of	sequences	compared	with	those	of	sequence	order-randomized	controls	(MFED)	(16). 
 
RESEARCH
sequences represent a substantial increase on the number 
of complete genome sequences obtained to date and have 
identified further examples of rarely reported genotype 1 
and 5 sequences, along with a putative new HPgV type 
(sample 89860282). In contrast, PCR amplicons are gen-
erally short and far less informative for strain identifica-
tion or phylogenetic analysis, particularly if derived from 
highly conserved regions of the genome, as was the case 
for the HHpgV-1 and HPgV PCRs used in this study.
The specificity and sensitivity of bioinformatic screen-
ing is critically dependent on library quality; sequences de-
rived from plasma samples or other largely acellular sam-
ples (cerebrospinal fluid, nasopharyngeal aspirates, urine) 
vary considerably in the numbers of contaminating host 
genomic sequences that may influence the effectiveness 
of screening for viral sequences in an unpredictable way 
(19). As demonstrated in this study, metagenomic librar-
ies may be variably affected by contaminating sequences 
originating from other samples in the sequencing run, or 
may be bioinformatically contaminated from errors in read-
ing identification tags for multiplexed sequencing reactions 
(20). In contrast, PCR-based screenings are capable of sin-
gle copy target sensitivity in a wide range of sample types, 
and appropriate laboratory and assay design can entirely 
avoid false-positive results arising from sample or reagent 
contamination (21).
In this study, results from the 2 detection approaches 
for HHpgV-1 viremia were consistent and demonstrat-
ed the rarity of viremia with this virus in groups most at 
risk for parenterally and sexually transmitted virus infec-
tions. For example, only 1 person in the HGDS cohort 
showed viremia for HHpgV-1, despite previous exten-
sive treatment with nonvirally inactivated factor VIII or 
IX concentrates (10). Exposure to bloodborne pathogens 
is attested by their universal seropositivity for HCV and 
high rate of HIV-1 infection (50% in those selected for 
this study). Despite the evidence for parenteral transmis-
sion of HHpgV-1 in the original study (6), our finding of 
a low frequency of detectable infection in this risk group 
is consistent with the originally reported low rate of vire-
mia among persons with hemophilia (2/106 [6]). HHpgV-1 
was similarly detected at low frequency in HCV-positive 
persons who inject drugs (2/120; Table 2), although 
persons in this risk group were almost universally infected 
with HCV from needle sharing.
In interpreting these results, we can rule out a poor se-
quence library or physical sample quality as the cause for 
nondetection of HHpgV-1. Viremia frequencies of the oth-
er pegivirus, HPgV, were comparable to those previously 
described in these risk groups, with elevated frequencies 
in those with histories of sexual exposure (8% in the HIV-
positive persons in this study) previously reported to have 
high rates of HPgV active infection (22–25). Elevated fre-
quencies are similarly reported in persons who inject drugs 
(26,27), which is consistent with the increased detection 
frequencies in this study (11%).
The findings of relatively low frequencies of HHpgV-1 
viremia in the groups screened in this study suggest that it 
circulates less in human populations than HPgV, HCV, or 
HIV-1 or that infections are associated with a higher rate of 
clearance than for these other bloodborne viruses. Persis-
tence over months or years was observed in 2 persons with 
hemophilia in the original study, although both blood re-
cipients infected with HHpgV-1 cleared viremia within 241 
and 281 days posttransfusion (6). The propensity of HH-
pgV-1 to persist for long periods, at least in some persons, 
is shared with many hepaciviruses and pegiviruses. Analy-
sis of the coding regions of the 2 HHpgV-1 variants de-
tected in this study revealed evidence for large-scale RNA 
secondary structure (mean folding energy differences of 
7.6% and 8.1%), similar to that of the originally described 
HHpgV-1 sequence (6). This finding is within the range 
of values previously associated with host persistence in a 
wide range of positive-stranded mammalian RNA viruses, 
including HCV and HPgV in humans (16,28). Neverthe-
less, given the extensive exposure of the HGDS cohort in-
vestigated in this study to bloodborne viruses, the absence 
of detectable HHpgV-1 viremia in all but 1 of the persons 
in this study is more consistent with a higher rate of virus 
clearance for HCV and HPgV in this group rather than a 
lack of exposure.
Our findings potentially mirror those of our previ-
ous investigation of the parenterally transmitted parvovi-
rus PARV4 in the HGDS cohort (29), where exposure is 
also closely associated with HCV and HIV through shared 
routes of transmission (30). Although all 195 study sub-
jects were PCR-negative for PARV4 DNA at the end of 
the study period, 44% were seropositive for anti-PARV4 
antibodies, and a process of acute infection followed by 
clearance was documented for a large number from whom 
serial samples were available over the period of infection. 
Without a serology assay for HHpgV-1, it is problematic 
to determine whether the lack of viremia detection in the 
HGDS cohort and other groups arose though lack of expo-
sure or high rates of clearance of viremia.
676	 Emerging	Infectious	Diseases	•	www.cdc.gov/eid	•	Vol.	22,	No.	4,	April	2016
 
 
 
Table 4. Validation	of	HPgV detection in	plasma	samples	by	
using	PCR* 
No.	
samples 
Metagenomic	
screen	results† 
 
Primers,	no.	positive 
HHpgV-1 HPgV Group	2 ak1/ak2‡ Group 1 
2 + –  2 2 0 
1 +/– –  0 0 0 
10 – +  0 0 10 
10 – –  0 0 0 
*HPgV,	human	pegivirus;	HHpgV,	human	hepegivirus;	+,	positive;	–,	
negative. 
†Virus status as determined by bioinformatic screening. 
‡Nonstructural 3 genes as previously described (6). 
 
	Novel	Human	Pegivirus	Evaluation
In summary, this study used 2 complementary and 
cross-validated screening approaches to document frequen-
cies of active infection of several different study groups 
with HHpgV-1 compared with other parenterally and sexu-
ally transmitted flaviviruses. Complementary screening of 
these risk groups for past exposure by using serology as-
says is required to understand more about its epidemiology, 
transmission routes, and host interactions.
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